

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.<sup>1</sup>

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**THIRTIETH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR  
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF  
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE  
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR  
THE PERIOD FROM MARCH 1, 2022 THROUGH MARCH 31, 2022**

Name of Applicant:

FTI Consulting, Inc.

Authorized to provide Professional Services  
to:

Ad Hoc Committee of Governmental and  
Other Contingent Litigation Claimants

Date of Order Approving Debtors' Payment  
of Fees and Expenses of Applicant:

December 2, 2019 [ECF No. 553]

Period for which compensation and  
reimbursement is sought:

March 1, 2022 through March 31,  
2022

Monthly Fees Incurred:

\$267,504.00

---

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$44.03

Total Fees and Expenses Due: \$267,548.03

This is a: X monthly \_\_\_\_ interim \_\_\_\_ final application

**PRIOR APPLICATIONS:**

<b>Docked No./Filed</b>	<b>Compensation Period</b>	<b>Requested</b>		<b>Approved</b>	
		<b>Fees</b>	<b>Expenses</b>	<b>Fees</b>	<b>Expenses</b>
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$372,253.00	\$96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$444,475.50	\$0.00
Docket No. 1850 Filed on 10/26/2020	8/1/2020 – 8/31/2020	\$261,092.00	\$108.25	\$258,592.00	\$108.25
Docket No. 1950 Filed on 10/26/2020	9/1/2020 – 9/30/2020	\$357,546.50	\$0.00	\$355,046.50	\$0.00
Docket No. 2031 Filed on 11/24/2020	9/19/2019 – 9/30/2020	\$44,462.00	\$0.00	\$41,462.60	\$0.00
Docket No. 2154 Filed on 12/18/2020	10/1/2020 – 10/31/2020	\$356,078.50	\$0.00	\$353,078.50	\$0.00
Docket No. 2308 Filed on 1/20/2021	11/1/2020 – 11/30/2020	\$450,827.00	\$0.00	\$447,827.00	\$0.00
Docket No. 2503 Filed on 3/17/2021	12/1/2020 – 12/31/2020	\$308,146.00	\$0.00	\$305,146.00	\$0.00
Docket No. 2504 Filed on 3/17/2021	1/1/2021 – 1/31/2021	\$493,773.50	\$0.00	\$490,773.50	\$0.00
Docket No. 2848 Filed on 5/12/2021	2/1/2021 – 2/28/2021	\$381,199.00	\$9.99	\$377,458.99	\$9.99
Docket No. 2849 Filed on 5/12/2021	3/1/2021 – 3/31/2021	\$513,645.00	\$0.00	\$509,895.00	\$0.00
Docket No. 3017 Filed on 6/11/2021	4/1/2021 – 4/30/2021	\$415,904.00	\$0.00	\$412,154.00	\$0.00
Docket No. 3225 Filed on 7/15/2021	5/1/2021 – 5/31/2021	\$363,711.00	\$40.00	\$360,001.00	\$40.00
Docket No. 3747 Filed on 9/9/2021	6/1/2021 – 6/30/2021	\$303,427.50	\$0.00	\$299,677.50	\$0.00

**PRIOR APPLICATIONS (cont.):**

<b>Docked No./Filed</b>	<b>Compensation Period</b>	<b>Requested</b>		<b>Approved</b>	
		<b>Fees</b>	<b>Expenses</b>	<b>Fees</b>	<b>Expenses</b>
Docket No. 3798 Filed on 9/21/2021	7/1/2021 – 7/31/2021	\$431,630.50	\$135.81	\$427,880.50	\$135.81
Docket No. 3941 Filed on 10/14/2021	8/1/2021 – 8/31/2021	\$284,159.00	\$20.94	\$280,409.00	\$20.94
Docket No. 4097 Filed on 11/11/2021	9/1/2021 – 9/30/2021	\$244,958.50	\$0.00	\$241,208.50	\$0.00
Docket No. 4225 Filed on 12/15/2021	10/1/2021 – 10/31/2021	\$368,998.50	\$40.00	\$367,498.50	\$40.00
Docket No. 4311 Filed on 1/26/2022	11/1/2021 – 11/30/2021	\$255,094.50	\$1,160.04	\$253,594.50	\$1,160.04
Docket No. 4312 Filed on 1/26/2022	12/1/2021 – 12/31/2021	\$192,786.50	\$0.00	\$191,286.50	\$0.00
Docket No. 4395 Filed on 2/25/2022	1/1/2022 – 1/31/2022	\$314,564.00	\$0.00	\$313,064.00	\$0.00
Docket No. 4654 Filed on 4/12/2022	2/1/2022 – 2/28/2022	\$181,198.50	\$8.00	\$144,952.40	\$8.00

Note: The fee examiner's agreed upon reductions of \$30,000, \$17,500, \$10,000, \$15,000, \$15,000, \$15,000, and \$6,000 were allocated evenly across fees from the first, second, third, fourth, fifth, sixth, and seventh interim period, respectively.

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from March 1, 2022 through and including March 31, 2022 (the “**Fee Period**”) amount to:

Professional Fees	\$267,504.00
Expenses	<u>44.03</u>
<b><u>TOTAL</u></b>	<b><u>\$267,548.03</u></b>

2. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$214,003.20
Expenses at 100%	<u>44.03</u>
<b><u>TOTAL</u></b>	<b><u>\$214,047.23</u></b>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fee Period are set forth on the schedule annexed hereto as **Exhibit “A”**.

4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “B”**.

5. Detailed time entry by task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “C”**.
6. A summary of expenses incurred during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “D”**.
7. Detailed breakdown of the expenses incurred during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “E”**.
8. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

#### **NOTICE AND OBJECTION PROCEDURES**

9. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than May 30, 2022 (the “**Objection Deadline**”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “**Objection**”).
10. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
11. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York  
May 16, 2022

FTI CONSULTING, INC.  
Financial Advisors to the Ad Hoc Committee of  
Governmental and Other Contingent Litigation  
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz  
Matthew Diaz, Senior Managing Director  
1166 Avenue of the Americas, 15<sup>th</sup> Floor  
New York, New York 10036  
Telephone: (212) 499-3611  
Email: matt.diaz@fticonsulting.com

**EXHIBIT A**

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**SUMMARY OF HOURS BY PROFESSIONAL**  
**FOR THE PERIOD MARCH 1, 2022 TO MARCH 31, 2022**

<b>Professional</b>	<b>Position</b>	<b>Specialty</b>	<b>Billing Rate</b>	<b>Total Hours</b>	<b>Total Fees</b>
Diaz, Matthew	Sr Managing Director	Restructuring	\$ 1,200	67.9	\$ 81,480.00
Joffe, Steven	Sr Managing Director	Tax	1,200	12.1	14,520.00
Simms, Steven	Sr Managing Director	Restructuring	1,325	5.8	7,685.00
Bromberg, Brian	Sr Director	Restructuring	890	117.0	104,130.00
Suric, Emil	Sr Director	Restructuring	890	8.2	7,298.00
Baron, Genevieve	Sr Consultant	Healthcare	375	0.5	187.50
Kurtz, Emma	Sr Consultant	Restructuring	655	79.7	52,203.50
<b>GRAND TOTAL</b>			<b>291.2</b>	<b>\$ 267,504.00</b>	

**EXHIBIT B****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY TASK****FOR THE PERIOD MARCH 1, 2022 TO MARCH 31, 2022**

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	21.3	\$ 17,180.50
2	Cash & Liquidity Analysis	0.6	720.00
7	Analysis of Domestic Business Plan	71.4	63,085.50
9	Analysis of Employee Comp Programs	37.2	35,164.50
10	Analysis of Tax Issues	1.7	2,040.00
11	Prepare for and Attend Court Hearings	15.6	15,654.00
16	Analysis, Negotiate and Form of POR & DS	119.3	111,719.50
21	General Mtgs with Counsel and/or Ad Hoc Committee	8.1	8,704.50
24	Preparation of Fee Application	8.9	6,810.50
26	Analysis of Insurance Programs	0.4	356.00
28	Review of IAC Business Plan	6.7	6,069.00
<b>GRAND TOTAL</b>		<b>291.2</b>	<b>\$ 267,504.00</b>

## EXHIBIT C

## PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

## DETAIL OF TIME ENTRIES

FOR THE PERIOD MARCH 1, 2022 TO MARCH 31, 2022

Task Category	Date	Professional	Hours	Activity
1	3/1/2022	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/2/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/3/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/4/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/7/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/8/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/9/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/10/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/11/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/14/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/15/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/16/2022	Diaz, Matthew	0.6	Review Debtors' current operating results.
1	3/16/2022	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/17/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/21/2022	Diaz, Matthew	1.3	Review the December operating report.
1	3/21/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/22/2022	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/23/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/24/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/25/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/28/2022	Kurtz, Emma	0.6	Review recently uploaded dataroom documents re: reporting to share with team.
1	3/28/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/29/2022	Bromberg, Brian	1.1	Review presentation re: update on business performance.
1	3/29/2022	Diaz, Matthew	0.7	Review Debtors' January financial update.
1	3/29/2022	Kurtz, Emma	2.6	Prepare presentation on Debtors' January financial performance.
1	3/29/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/30/2022	Bromberg, Brian	0.4	Review latest draft of January business performance update presentation.
1	3/30/2022	Bromberg, Brian	0.7	Provide further comments on January operating update presentation.
1	3/30/2022	Diaz, Matthew	0.7	Review draft presentation re: January operating report.
1	3/30/2022	Kurtz, Emma	0.4	Prepare revisions to January operating report update to reflect internal comments.
1	3/30/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	3/31/2022	Bromberg, Brian	0.9	Review January update presentation to provide comments.
1	3/31/2022	Bromberg, Brian	0.9	Review OTC performance for January 2022.
1	3/31/2022	Diaz, Matthew	0.9	Review presentation to the Committee on YTD actual results.
1	3/31/2022	Kurtz, Emma	1.1	Prepare revisions to report on January operating performance and draft accompanying summary email.
1	3/31/2022	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.

## EXHIBIT C

## PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

## DETAIL OF TIME ENTRIES

FOR THE PERIOD MARCH 1, 2022 TO MARCH 31, 2022

Task Category	Date	Professional	Hours	Activity
<b>1 Total</b>			<b>21.3</b>	
<b>2</b>	3/3/2022	Diaz, Matthew	0.6	Review updated cash flow analysis.
<b>2 Total</b>			<b>0.6</b>	
7	3/1/2022	Bromberg, Brian	1.3	Participate in financial advisor business plan call.
7	3/1/2022	Diaz, Matthew	1.5	Participate in call with the financial advisors to the Debtors and the UCC to discuss business plan.
7	3/1/2022	Diaz, Matthew	1.4	Prepare for call with the Debtors on open financial issues re: business plan.
7	3/2/2022	Bromberg, Brian	0.6	Compile prior forecast models and actual performance re: OxyContin sales.
7	3/2/2022	Kurtz, Emma	1.2	Prepare revisions to cost presentation per internal comments.
7	3/2/2022	Suric, Emil	3.1	Prepare updates to OxyContin scenario based projections.
7	3/3/2022	Kurtz, Emma	2.2	Prepare additional revisions to the cost analysis to include additional summary analyses.
7	3/3/2022	Kurtz, Emma	1.8	Continue to prepare summary analyses to include in draft cost report.
7	3/3/2022	Suric, Emil	1.9	Continue to prepare updates to OxyContin forecast model.
7	3/4/2022	Kurtz, Emma	1.8	Finalize revisions to cost analysis per internal comments.
7	3/8/2022	Bromberg, Brian	2.9	Review updated draft of the cost presentation.
7	3/8/2022	Diaz, Matthew	1.1	Review updated cost analysis and presentation.
7	3/9/2022	Bromberg, Brian	0.6	Review updates to cost report.
7	3/9/2022	Kurtz, Emma	1.3	Review updated draft of cost analysis to provide comments.
7	3/10/2022	Bromberg, Brian	1.0	Review OxyContin forecast for 2021.
7	3/11/2022	Bromberg, Brian	0.3	Review summary analysis of manufacturing plant options.
7	3/14/2022	Baron, Genevieve	0.5	Attend call with internal team to discuss Wilson manufacturing plant.
7	3/14/2022	Bromberg, Brian	1.9	Compare OxyContin model to prior years version.
7	3/14/2022	Bromberg, Brian	1.1	Review OxyContin sales models.
7	3/14/2022	Bromberg, Brian	0.7	Review analysis of manufacturing site to prepare for call.
7	3/14/2022	Bromberg, Brian	0.5	Participate in call with team on manufacturing site.
7	3/14/2022	Bromberg, Brian	0.6	Participate in call with team on Oxycontin sales forecast.
7	3/14/2022	Diaz, Matthew	0.9	Review next steps on the cost report.
7	3/14/2022	Diaz, Matthew	0.9	Review updated OxyContin forecast and related analysis.
7	3/14/2022	Kurtz, Emma	2.1	Prepare analysis of historical OxyContin budget to actual performance.
7	3/14/2022	Kurtz, Emma	0.5	Attend call with FTI team to discuss Wilson manufacturing options.
7	3/14/2022	Kurtz, Emma	0.5	Attend call with internal team to discuss OxyContin forecast analysis.
7	3/14/2022	Kurtz, Emma	1.4	Review OxyContin forecast models to understand drivers of net sales.
7	3/14/2022	Suric, Emil	0.5	Attend call with internal team to discuss updated OxyContin forecast model.
7	3/15/2022	Bromberg, Brian	1.2	Review OxyContin model comparison.
7	3/15/2022	Bromberg, Brian	0.3	Review business plan forecast for Rhodes.
7	3/15/2022	Bromberg, Brian	0.3	Review business plan forecast for branded.
7	3/15/2022	Diaz, Matthew	1.2	Review updated cost report to evaluate changes.
7	3/15/2022	Kurtz, Emma	2.4	Prepare comparison of 2021 OxyContin forecast model to actual 2021 results to identify drivers of out-performance.
7	3/16/2022	Bromberg, Brian	1.3	Review prior business plan forecasts to evaluate out-performance.
7	3/16/2022	Bromberg, Brian	0.4	Review pipeline materials related to latest business plan.
7	3/21/2022	Bromberg, Brian	0.6	Review Debtors' latest business plan.
7	3/21/2022	Diaz, Matthew	0.7	Review Debtors' 2021 PHI spend.
7	3/22/2022	Bromberg, Brian	0.3	Review sales forecast model.
7	3/23/2022	Bromberg, Brian	1.7	Review pipeline materials to prepare for pipeline meeting.
7	3/23/2022	Bromberg, Brian	1.4	Prepare summary of pipeline spend and identify certain issues.
7	3/23/2022	Bromberg, Brian	1.3	Participate in call with the Debtors and their advisors to discuss PHI pipeline.
7	3/23/2022	Bromberg, Brian	0.7	Review business plan PHI materials.
7	3/23/2022	Diaz, Matthew	1.0	Attend partial call with the Debtors re: PHI.
7	3/23/2022	Kurtz, Emma	1.2	Attend call with the Debtors and their advisors to discuss PHI.
7	3/23/2022	Suric, Emil	1.2	Attend call with the Debtors to discuss the PHI projections.
7	3/24/2022	Bromberg, Brian	0.4	Review PHI materials related to the latest business plan.
7	3/24/2022	Bromberg, Brian	0.4	Summarize issues related to projected pipeline spend.
7	3/24/2022	Bromberg, Brian	1.0	Participate in pipeline update call with the Debtors and their advisors.
7	3/24/2022	Diaz, Matthew	0.9	Attend partial call with the Debtors re: pipeline.
7	3/24/2022	Kurtz, Emma	1.0	Attend call with the Debtors and the Debtors' advisors to discuss the for profit pipeline.
7	3/24/2022	Suric, Emil	1.0	Attend call with the Debtors to discuss the economics of pipeline, both for profit and non-profit.
7	3/25/2022	Bromberg, Brian	0.4	Review OxyContin sales forecast model.

## EXHIBIT C

## PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

## DETAIL OF TIME ENTRIES

FOR THE PERIOD MARCH 1, 2022 TO MARCH 31, 2022

Task Category	Date	Professional	Hours	Activity
7	3/25/2022	Bromberg, Brian	0.5	Attend call with Province to discuss the for profit pipeline update.
7	3/25/2022	Bromberg, Brian	1.1	Prepare summary of pipeline issues.
7	3/25/2022	Diaz, Matthew	0.6	Participate in a call with Houlihan and the UCC financial advisors to discuss the pipeline and PHI products.
7	3/25/2022	Diaz, Matthew	0.9	Review updated pipeline products.
7	3/25/2022	Diaz, Matthew	0.6	Review updated PHI programs.
7	3/25/2022	Kurtz, Emma	0.5	Attend call with HL and Province to discuss potential response to PHI and pipeline updates from the Debtors.
7	3/25/2022	Suric, Emil	0.5	Attend call with HL and UCC advisors to discuss the Debtors' pipeline and PHI plans.
7	3/28/2022	Bromberg, Brian	1.1	Review additional pipeline materials provided by the Debtors.
7	3/28/2022	Bromberg, Brian	0.5	Participate on call with the Debtors advisors re: pipeline update.
7	3/28/2022	Bromberg, Brian	0.6	Prepare summary update re: pipeline and public health initiatives.
7	3/28/2022	Diaz, Matthew	0.5	Participate in call with the Debtors' advisors on the pipeline.
7	3/29/2022	Bromberg, Brian	0.6	Review Debtors' PHI materials and analyses.
7	3/29/2022	Diaz, Matthew	0.8	Review Debtors' PHI analysis.
7	3/29/2022	Diaz, Matthew	0.9	Review Debtors' pipeline analysis.
7	3/30/2022	Bromberg, Brian	0.6	Review Debtors' business plan materials re: pipeline.
7	3/31/2022	Bromberg, Brian	0.8	Review updated draft cost report.
7	3/31/2022	Bromberg, Brian	0.6	Review updated cost presentation to provide comments to team.
7	3/31/2022	Kurtz, Emma	1.3	Prepare updates to cost analysis presentation to reflect latest information from Alix.
<b>7 Total</b>			<b>71.4</b>	
9	3/3/2022	Diaz, Matthew	0.5	Participate in call with Alix to discuss the KEIP/KERP.
9	3/9/2022	Bromberg, Brian	0.5	Discuss proposed 2022 KEIP scorecard with team.
9	3/9/2022	Bromberg, Brian	0.6	Review 2021 scorecard performance against metrics.
9	3/9/2022	Bromberg, Brian	0.7	Review proposed 2022 scorecard metrics.
9	3/9/2022	Bromberg, Brian	0.4	Review UCC comments on scorecard.
9	3/10/2022	Bromberg, Brian	1.2	Review scorecard metrics and evaluate changes.
9	3/10/2022	Bromberg, Brian	0.6	Attend call with HL to discuss the Debtors' proposed 2022 scorecard.
9	3/10/2022	Bromberg, Brian	0.3	Attend call with UCC advisors re: proposed 2022 scorecard.
9	3/10/2022	Bromberg, Brian	1.2	Compile comments on the scorecard.
9	3/10/2022	Bromberg, Brian	0.3	Review UCC comments on scorecard.
9	3/10/2022	Diaz, Matthew	0.7	Review of the proposed KEIP scorecard.
9	3/10/2022	Diaz, Matthew	0.5	Participate in call with Houlihan on the proposed KEIP scorecard.
9	3/10/2022	Kurtz, Emma	1.4	Evaluate 2021 KEIP scorecard results to validate scoring.
9	3/10/2022	Kurtz, Emma	1.3	Prepare analysis of proposed 2022 KEIP scorecard metrics.
9	3/10/2022	Kurtz, Emma	0.6	Attend call with HL to discuss 2021 KEIP scorecard results and proposed 2022 KEIP scorecard metrics.
9	3/11/2022	Bromberg, Brian	0.9	Review UCC comments on Debtors' proposed 2022 scorecard.
9	3/11/2022	Bromberg, Brian	0.9	Review scorecard comments.
9	3/11/2022	Bromberg, Brian	0.6	Attend call with internal team to discuss comments on 2022 scorecard with team.
9	3/11/2022	Bromberg, Brian	1.3	Combine comments on scorecard from advisors.
9	3/11/2022	Bromberg, Brian	0.5	Discuss scorecard comments with UCC advisors.
9	3/11/2022	Bromberg, Brian	0.9	Finalize comments on scorecard to share with Debtors.
9	3/11/2022	Diaz, Matthew	0.6	Review of the 2021 scorecard results.
9	3/11/2022	Diaz, Matthew	0.9	Review of the proposed 2022 scorecard.
9	3/11/2022	Diaz, Matthew	1.3	Review of the updated scorecard analysis.
9	3/11/2022	Diaz, Matthew	0.4	Participate in call with the UCC to discuss the proposed KEIP scorecard.
9	3/11/2022	Kurtz, Emma	0.5	Attend call with team to discuss 2021 and 2022 KEIP scorecards.
9	3/11/2022	Kurtz, Emma	0.5	Attend call with HL and Province to discuss responses to Debtors 2021 and 2022 KEIP scorecards.
9	3/14/2022	Diaz, Matthew	0.5	Participate in call with Alix to discuss the proposed scorecards.
9	3/14/2022	Diaz, Matthew	0.7	Review historical employee compensation plans.
9	3/17/2022	Bromberg, Brian	1.7	Review revised proposed 2022 scorecard and compare to prior scorecards.
9	3/17/2022	Diaz, Matthew	0.8	Review of employee incentive issues.
9	3/18/2022	Bromberg, Brian	0.6	Draft list of employee incentive issues.
9	3/18/2022	Bromberg, Brian	0.4	Attend call with the Debtors advisors to discuss the proposed 2022 scorecard.
9	3/18/2022	Bromberg, Brian	0.4	Prepare summary of scorecard discussion with the Debtors advisors.
9	3/18/2022	Bromberg, Brian	0.9	Review 2021 scorecard scoring.
9	3/18/2022	Bromberg, Brian	0.4	Review pipeline materials related to 2021 scorecard scoring.

## EXHIBIT C

## PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

## DETAIL OF TIME ENTRIES

FOR THE PERIOD MARCH 1, 2022 TO MARCH 31, 2022

Task Category	Date	Professional	Hours	Activity
9	3/18/2022	Diaz, Matthew	0.5	Participate in call with Alix to discuss employee performance scorecards.
9	3/18/2022	Diaz, Matthew	0.9	Review employee compensation issues and related next steps.
9	3/21/2022	Bromberg, Brian	1.3	Draft proposed response to the Debtors 2022 scorecard.
9	3/21/2022	Bromberg, Brian	0.6	Discuss 2022 scorecard proposal with UCC advisors.
9	3/21/2022	Diaz, Matthew	0.6	Participate in call with the Province and Houlihan to discuss the employee scorecards.
9	3/22/2022	Bromberg, Brian	1.0	Consult with counsel on scorecard proposal.
9	3/22/2022	Bromberg, Brian	0.6	Prepare revisions to AHC/UCC scorecard proposal.
9	3/22/2022	Diaz, Matthew	0.6	Review proposed changes to the 2022 scorecard.
9	3/23/2022	Diaz, Matthew	0.4	Draft correspondence on the employee incentive plan to counsel and related next steps.
9	3/23/2022	Diaz, Matthew	0.6	Review a certain employee's employment agreement.
9	3/23/2022	Kurtz, Emma	0.8	Prepare comparison of new CFO compensation package to prior CFO compensation under the KEIP.
9	3/24/2022	Bromberg, Brian	0.9	Revise 2022 scorecard counterproposal to share with the Debtors.
9	3/24/2022	Bromberg, Brian	0.7	Review executive compensation.
9	3/28/2022	Bromberg, Brian	1.2	Review Debtors' response to proposal on scorecard.
<b>9 Total</b>			<b>37.2</b>	
10	3/1/2022	Joffe, Steven	1.2	Participate in weekly AHC call to discuss case updates, with a focus on potential tax issues.
10	3/23/2022	Joffe, Steven	0.5	Participate in weekly AHC call re: case updates, with a focus on potential tax issues.
<b>10 Total</b>			<b>1.7</b>	
11	3/2/2022	Bromberg, Brian	0.4	Attend hearing re: preliminary injunction extension.
11	3/9/2022	Bromberg, Brian	1.3	Listen to settlement hearing.
11	3/9/2022	Bromberg, Brian	1.1	Continue to listen to settlement hearing.
11	3/9/2022	Diaz, Matthew	2.4	Attend partial settlement hearing.
11	3/9/2022	Joffe, Steven	2.3	Attend hearing re: settlement motion.
11	3/9/2022	Joffe, Steven	2.1	Continue to attend hearing re: settlement motion.
11	3/9/2022	Kurtz, Emma	2.6	Attend hearing re: settlement motion.
11	3/9/2022	Kurtz, Emma	1.8	Continue to attend hearing re: settlement motion.
11	3/9/2022	Simms, Steven	1.6	Listen to hearing on settlement agreement.
<b>11 Total</b>			<b>15.6</b>	
16	3/1/2022	Bromberg, Brian	2.3	Prepare revisions to draft HRT slides.
16	3/1/2022	Bromberg, Brian	0.7	Participate in call re: HRT with counsel.
16	3/1/2022	Bromberg, Brian	1.2	Review past objections to HRT funding requests.
16	3/1/2022	Bromberg, Brian	1.7	Prepare further revisions to HRT presentation.
16	3/1/2022	Diaz, Matthew	1.4	Review draft slides re: HRT update and funding request.
16	3/1/2022	Kurtz, Emma	1.3	Attend call with HL and counsel to discuss proposed HRT funding.
16	3/1/2022	Kurtz, Emma	1.4	Prepare revisions to presentation re: HRT funding request and OTC naloxone update per internal comments.
16	3/1/2022	Kurtz, Emma	1.5	Attend bi-weekly call with all advisors to discuss case updates and emergence preparation.
16	3/1/2022	Kurtz, Emma	0.9	Prepare further revisions to HRT and OTC naloxone update presentation.
16	3/2/2022	Bromberg, Brian	1.4	Finalize HRT presentation.
16	3/2/2022	Bromberg, Brian	1.3	Prepare revisions to presentation re: HRT funding agreement.
16	3/2/2022	Bromberg, Brian	0.7	Review HRT reports from the Debtors.
16	3/2/2022	Diaz, Matthew	1.2	Review updated draft of the HRT committee presentation.
16	3/2/2022	Diaz, Matthew	1.7	Review HRT funding agreement and related motion.
16	3/2/2022	Diaz, Matthew	0.4	Review injunctive relief summary.
16	3/2/2022	Diaz, Matthew	0.8	Review mediation update from counsel.
16	3/2/2022	Kurtz, Emma	1.1	Review mediation update and draft settlement term sheet.
16	3/2/2022	Kurtz, Emma	1.6	Review HRT motion and proposed funding agreement.
16	3/2/2022	Simms, Steven	0.4	Review mediation update.
16	3/3/2022	Bromberg, Brian	1.2	Review Sackler asset coverage presentations.
16	3/3/2022	Bromberg, Brian	1.9	Review mediation term sheet.
16	3/3/2022	Bromberg, Brian	0.7	Analyze implications of additional settlement agreement on collateral.
16	3/3/2022	Bromberg, Brian	1.7	Review presentation re: Sackler asset coverage of additional settlement obligations.
16	3/3/2022	Bromberg, Brian	0.9	Review asset coverage assumptions.
16	3/3/2022	Bromberg, Brian	0.6	Attend call with internal team to discuss asset coverage ratios.
16	3/3/2022	Bromberg, Brian	0.6	Attend call with HL and counsel to discuss settlement obligation impact on asset coverage.
16	3/3/2022	Diaz, Matthew	0.6	Review extension of the preliminary injunction.
16	3/3/2022	Diaz, Matthew	0.9	Review settlement term sheet.

## EXHIBIT C

## PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

## DETAIL OF TIME ENTRIES

## FOR THE PERIOD MARCH 1, 2022 TO MARCH 31, 2022

Task Category	Date	Professional	Hours	Activity
16	3/3/2022	Diaz, Matthew	1.9	Perform detailed review of the updated collateral analysis and related slides.
16	3/3/2022	Kurtz, Emma	2.4	Prepare analysis of Sackler asset settlement obligation coverage ratios to reflect additional payments contemplated in the mediation term sheet.
16	3/3/2022	Kurtz, Emma	0.6	Attend call with counsel and HL to discuss the IAC update and Sackler settlement obligation coverage ratios.
16	3/3/2022	Kurtz, Emma	1.2	Prepare presentation re: impact of mediation term sheet on asset coverage ratios.
16	3/3/2022	Kurtz, Emma	1.3	Prepare revisions to presentation re: impact of term sheet on settlement obligation coverage.
16	3/3/2022	Kurtz, Emma	0.5	Attend call with internal team to discuss comments on presentation re: mediation term sheet impact on asset coverage ratios.
16	3/3/2022	Kurtz, Emma	1.4	Prepare revisions to draft presentation re: term sheet coverage impact per comments from team.
16	3/4/2022	Bromberg, Brian	1.4	Review coverage presentation to provide comments to team.
16	3/4/2022	Bromberg, Brian	0.6	Participate in call with counsel and HL re: coverage ratios.
16	3/4/2022	Bromberg, Brian	1.7	Participate in weekly AHC call to discuss case updates re: mediation term sheet.
16	3/4/2022	Bromberg, Brian	0.8	Review objections to the additional Sackler settlement.
16	3/4/2022	Bromberg, Brian	1.1	Review terms of the additional settlement agreement.
16	3/4/2022	Diaz, Matthew	1.6	Review of the updated plan b analysis.
16	3/4/2022	Diaz, Matthew	0.6	Participate in call with counsel and Houlihan to discuss the updated settlement analysis.
16	3/4/2022	Kurtz, Emma	1.7	Prepare updates to term sheet coverage deck before call with HL and counsel.
16	3/4/2022	Kurtz, Emma	0.6	Attend call with HL and counsel to discuss impact of mediation term sheet on Sackler settlement obligation coverage ratios.
16	3/7/2022	Bromberg, Brian	3.6	Review updated draft settlement agreement.
16	3/7/2022	Bromberg, Brian	1.4	Review SOAF agreement.
16	3/7/2022	Bromberg, Brian	1.1	Attend AHC call to discuss proposed settlement and potential response.
16	3/7/2022	Bromberg, Brian	1.2	Review team questions on settlement agreement.
16	3/7/2022	Bromberg, Brian	1.3	Review IAC structure relative to settlement agreement.
16	3/7/2022	Diaz, Matthew	1.1	Participate in call with the AHC to discuss the proposed settlement.
16	3/7/2022	Diaz, Matthew	0.6	Review draft ad hoc committee objection to the settlement term sheet.
16	3/7/2022	Diaz, Matthew	1.1	Review mediator's 4th interim report.
16	3/7/2022	Diaz, Matthew	0.6	Review Debtors' motion to approve the term sheet.
16	3/7/2022	Diaz, Matthew	1.9	Review updated Sackler settlement agreement.
16	3/7/2022	Diaz, Matthew	1.3	Review SOAF settlement agreement.
16	3/7/2022	Joffe, Steven	1.1	Review objections to additional settlement.
16	3/7/2022	Kurtz, Emma	1.4	Review revised exhibit F to the shareholder settlement agreement to evaluate changes.
16	3/7/2022	Kurtz, Emma	1.7	Review redline of MDT agreement to understand changes.
16	3/7/2022	Kurtz, Emma	1.4	Review proposed SOAF agreement to evaluate terms.
16	3/7/2022	Kurtz, Emma	1.3	Prepare summary of changes to settlement agreements to incorporate additional Sackler settlement.
16	3/7/2022	Simms, Steven	0.4	Review update re: proposed settlement term sheet.
16	3/8/2022	Bromberg, Brian	0.7	Attend internal call to discuss revised settlement agreement and SOAF agreement with team.
16	3/8/2022	Bromberg, Brian	1.4	Review settlement agreement.
16	3/8/2022	Bromberg, Brian	0.7	Review AHC objection to settlement agreement.
16	3/8/2022	Bromberg, Brian	0.5	Review presentation on OTC naloxone.
16	3/8/2022	Bromberg, Brian	0.6	Review revised settlement agreement examples.
16	3/8/2022	Bromberg, Brian	1.7	Review settlement agreement mechanics to evaluate necessary updates.
16	3/8/2022	Diaz, Matthew	0.6	Review AHC objection to the settlement.
16	3/8/2022	Diaz, Matthew	1.4	Review updated settlement agreements.
16	3/8/2022	Kurtz, Emma	0.6	Discuss changes to settlement agreement and draft SOAF agreement with internal team.
16	3/8/2022	Kurtz, Emma	1.2	Prepare revisions to settlement agreement example files due to updated settlement.
16	3/8/2022	Kurtz, Emma	1.2	Review AHC objection to settlement agreement.
16	3/9/2022	Bromberg, Brian	0.8	Review materials to prepare for call with counsel re: settlement agreements.
16	3/9/2022	Bromberg, Brian	0.5	Participate in call with counsel on settlement agreements.
16	3/9/2022	Bromberg, Brian	1.1	Draft recommendation re: HRT funding request.
16	3/9/2022	Bromberg, Brian	0.7	Review draft slides re: OTC naloxone to provide comments.
16	3/9/2022	Diaz, Matthew	0.6	Review Debtors' proposed HRT agreement.
16	3/9/2022	Diaz, Matthew	0.5	Review UST objection to the settlement.
16	3/9/2022	Diaz, Matthew	0.7	Review Debtors' reply in support of the settlement.
16	3/9/2022	Joffe, Steven	1.4	Review statements in support of the settlement.

## EXHIBIT C

## PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

## DETAIL OF TIME ENTRIES

## FOR THE PERIOD MARCH 1, 2022 TO MARCH 31, 2022

Task Category	Date	Professional	Hours	Activity
16	3/9/2022	Kurtz, Emma	0.5	Attend call with counsel to discuss changes to settlement agreement and draft SOAF agreement.
16	3/10/2022	Bromberg, Brian	0.6	Review settlement agreement.
16	3/10/2022	Diaz, Matthew	0.6	Review summaries of the settlement hearing.
16	3/11/2022	Diaz, Matthew	1.6	Review updated settlement agreement and related documents.
16	3/14/2022	Bromberg, Brian	0.4	Review potential issues with HRT funding agreement.
16	3/14/2022	Bromberg, Brian	1.3	Prepare summary on naloxone to answer questions from team.
16	3/14/2022	Diaz, Matthew	0.6	Review summaries of second circuit briefing on the appeal.
16	3/15/2022	Bromberg, Brian	1.1	Participate in biweekly call with Debtors to discuss status of business operations and preparations for emergency.
16	3/15/2022	Bromberg, Brian	0.4	Review agenda to prepare for biweekly professionals call with the Debtors.
16	3/15/2022	Diaz, Matthew	1.0	Participate in a call with Debtors' advisors to discuss current financial topics.
16	3/15/2022	Kurtz, Emma	1.0	Attend biweekly professionals call to discuss business operations and emergency preparation.
16	3/15/2022	Simms, Steven	0.4	Review update from team following bi-weekly professionals call.
16	3/16/2022	Bromberg, Brian	0.6	Draft potential responses to HRT funding motion.
16	3/17/2022	Bromberg, Brian	0.9	Attend call with UCC advisors to discuss naloxone funding motion.
16	3/17/2022	Bromberg, Brian	0.8	Research UCC advisors' questions on naloxone.
16	3/17/2022	Bromberg, Brian	0.7	Review historical financials for naloxone development spend with HRT.
16	3/17/2022	Diaz, Matthew	0.4	Review next steps related to the HRT funding request.
16	3/18/2022	Simms, Steven	0.4	Review case updates, with a focus on the Debtors' HRT funding motion.
16	3/21/2022	Diaz, Matthew	0.9	Review 2nd circuit draft brief.
16	3/22/2022	Diaz, Matthew	0.9	Review of select sections of the Purdue Amicus briefs.
16	3/22/2022	Joffe, Steven	1.6	Review of briefs filed in appeal.
16	3/22/2022	Simms, Steven	0.6	Review draft second circuit brief.
16	3/23/2022	Bromberg, Brian	0.6	Review case updates to prepare for AHC call.
16	3/23/2022	Diaz, Matthew	0.3	Review hearing summaries on the injunction and the HRT motion.
16	3/23/2022	Kurtz, Emma	0.6	Review briefs filed in the appeal.
16	3/24/2022	Diaz, Matthew	1.4	Review 2nd circuit reply brief.
16	3/25/2022	Bromberg, Brian	0.8	Participate in internal call to discuss case updates related to emergence.
16	3/25/2022	Bromberg, Brian	0.4	Review materials to prepare for meeting with team.
16	3/25/2022	Kurtz, Emma	0.7	Attend call with team to discuss case updates re: emergence.
16	3/28/2022	Diaz, Matthew	0.7	Review summary of the reply briefs.
16	3/28/2022	Simms, Steven	0.4	Review summary from Counsel re: appeal reply briefs.
16	3/29/2022	Bromberg, Brian	0.4	Prepare for call with Debtors' advisors re: case updates.
16	3/29/2022	Bromberg, Brian	0.6	Participate in call with the Debtors' advisors on business updates.
16	3/29/2022	Bromberg, Brian	0.2	Review mediation order.
16	3/29/2022	Diaz, Matthew	0.5	Participate in call with the Debtors and UCC's advisers to discuss current financial topics.
16	3/29/2022	Kurtz, Emma	0.7	Attend bi-weekly call with the Debtors and other advisors to discuss case updates and business operations.
16	3/29/2022	Simms, Steven	0.3	Review mediation order.
16	3/30/2022	Bromberg, Brian	0.6	Review appellate briefs.
16	3/30/2022	Joffe, Steven	1.9	Review briefs filed in response to UST briefs.
<b>16 Total</b>			<b>119.3</b>	
21	3/1/2022	Bromberg, Brian	1.0	Participate in weekly AHC call re: mediation.
21	3/1/2022	Diaz, Matthew	1.3	Participate in AHC call to discuss the proposed settlement and related next steps.
21	3/1/2022	Simms, Steven	0.7	Attend weekly AHC call to discuss case status re: proposed settlement.
21	3/2/2022	Bromberg, Brian	1.5	Participate in weekly AHC call re: mediation updates.
21	3/3/2022	Diaz, Matthew	0.5	Participate in call with counsel to discuss Committee next steps.
21	3/4/2022	Diaz, Matthew	0.7	Participate in partial AHC call to discuss the proposed settlement.
21	3/23/2022	Bromberg, Brian	1.3	Participate in weekly AHC call to discuss case updates.
21	3/23/2022	Diaz, Matthew	0.5	Participate in the AHC call to discuss case status, with a focus on the appeal.
21	3/23/2022	Simms, Steven	0.6	Attend weekly AHC call to discuss case updates.
<b>21 Total</b>			<b>8.1</b>	
24	3/8/2022	Kurtz, Emma	1.2	Finalize draft of the seventh interim fee application per local rules.
24	3/9/2022	Diaz, Matthew	1.1	Review draft seventh interim fee application.
24	3/10/2022	Kurtz, Emma	0.7	Prepare revisions to seventh interim fee application.
24	3/22/2022	Kurtz, Emma	3.1	Begin to prepare February fee application per local rules.
24	3/23/2022	Kurtz, Emma	1.4	Continue to prepare draft February fee application per fee examiner guidelines.

## PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

## DETAIL OF TIME ENTRIES

FOR THE PERIOD MARCH 1, 2022 TO MARCH 31, 2022

Task Category	Date	Professional	Hours	Activity
24	3/28/2022	Diaz, Matthew	0.7	Review of the February fee statement.
24	3/28/2022	Kurtz, Emma	0.7	Prepare revisions to draft February fee statement.
<b>24 Total</b>			<b>8.9</b>	
26	3/16/2022	Bromberg, Brian	0.4	Review insurance discussion.
<b>26 Total</b>			<b>0.4</b>	
28	3/1/2022	Bromberg, Brian	1.0	Review prior IAC information provided on financial performance.
28	3/2/2022	Bromberg, Brian	1.0	Participate in call with IAC management to discuss sale process and financial update.
28	3/2/2022	Bromberg, Brian	1.7	Review IAC update re: sales process and operating performance.
28	3/2/2022	Diaz, Matthew	1.1	Review IAC update re: financial performance and sales process.
28	3/2/2022	Kurtz, Emma	1.0	Attend call with Debtors advisors to discuss update on IAC financial performance and sale process.
28	3/3/2022	Bromberg, Brian	0.9	Review IAC diligence questions.
<b>28 Total</b>			<b>6.7</b>	
<b>Grand Total</b>			<b>291.2</b>	

**EXHIBIT D****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF EXPENSES****FOR THE PERIOD MARCH 1, 2022 TO MARCH 31, 2022**

<b>Expense Type</b>	<b>Amount</b>
Transportation	\$ 24.03
Working Meals	20.00
<b>Grand Total</b>	<b>\$ 44.03</b>

1. Working Meals have been voluntarily reduced to the lesser of \$20 per person or the actual amount charged.

## EXHIBIT E

## PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

## EXPENSE DETAIL

FOR THE PERIOD MARCH 1, 2022 TO MARCH 31, 2022

Date	Professional	Expense Type	Expense Detail	Amount
3/3/2022	Kurtz, Emma	Transportation	Taxi - Emma Kurtz, Office - 1166 Avenue of Americas - Home. Uber home after working late in the office on Purdue Pharma case.	\$ 24.03
		<b>Transportation Total</b>		<b>\$ 24.03</b>
3/3/2022	Kurtz, Emma	Working Meals	Dinner while working late on case.	20.00
		<b>Working Meals Total</b>		<b>\$ 20.00</b>
		<b>Grand Total</b>		<b>\$ 44.03</b>